Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.
A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day). The plasma concentrations of procainamide and N-acetyl procainamide were at subtherapeutic levels. Discontinuation of procainamide led to complete recovery. A bone marrow aspiration showed slight hypoplasia with normocellular marrow. Lupus erythematosus (LE) and antinuclear antibody (ANA) tests were negative. The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed. Precautionary measures for the early recognition of this grave hazard in exposed patients are advocated. The physician should be aware of this complication before in initiating treatment with this drug.
D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced* / Q000473:pathology; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000209:etiology*; D001772:Blood Cell Count; D003692:Delayed-Action Preparations; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000150:complications*; D011342:Procainamide / Q000009:adverse effects* / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D003692:Delayed-Action Preparations; D011342:Procainamide